［1］BAI S,GUO W,FENG Y,et al.Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder:A systematic review and Meta-analysis of randomised controlled trials［J］.J Neurol Neurosurg Psychiatry，2020，91(1):21-32.
［2］IARC.Global cancer burden growing，amidst mounting need for services［EB/OL］.(2024-02-01)［2024-02-05］.https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing-amidst-mounting-need-for-services.
［3］HU K,SJLANDER A,LU D,et al.Aspirin and other non-steroidal anti-inflammatory drugs and depression,anxiety,and stress-related disorders following a cancer diagnosis a nationwide register-based cohort study［J］.BMC Med，2020，18(1):238.
［4］ZHANG XY,DU RL,LUO N,et al.Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner［J］.Stem Cell Res Ther，2020，11(1):370.
［5］SANKARANARAYANAN R,KUMAR DR,ALTINOZ MA,et al.Mechanisms of colorectal cancer prevention by aspirin-A literature review and perspective on the role of COX-dependent and-independent pathways［J］.Int J Mol Sci，2020,21(23)：9018.
［6］WU QB,YAO XJ,CHEN HW,et al.Long-term aspirin use for primary cancer prevention an updated systematic review and subgroup Meta-analysis of 29 randomized clinical trials［J］.J Cancer，2020，11(21)：6460-6473.
［7］MABROK HB,MOHAMED MS.Induction of COX-1,suppression of COX-2 and pro-inflammatory cytokines gene expression by moringa leaves and its aqueous extract in aspirin-induced gastric ulcer rats［J］.Mol Biol Rep，2019，46(4):4213-4224.
［8］PATRIGNANI P,PATRONO C.Aspirin and cancer［J］.Journal of the American College of Cardiology,2016，68:967-976.
［9］DOVIZIO M,ALBERTI S,GUILLEM-LLOBAT P,et al.Role of platelets in inflammation and cancer:Novel therapeutic strategies［J］.Basic Clin Pharmacol Toxicol,2014，114(1):118-127.
［10］SON DS,WILSON AJ,PARL AK，et al.The effects of the histone deacetylase inhibitor romidepsin(FK228) are enhanced by aspirin(ASA) in COX-1 positive ovarian cancer cells through augmentation of p21［J］.Cancer Biol Ther，2010，9(11):928-935.
［11］LUCOTTI S,CERUTTI C,SOYER M,et al.Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2［J］.J Clin Invest，2019，129(5):1845-1862.
［12］QORRI B,HARLESS W,SZEWCZUK MR.Novel molecular mechanism of aspirin and celecoxib targeting mammalian neuraminidase-1 impedes epidermal growth factor receptor signaling axis and induces apoptosis in pancreatic cancer cells［J］.Drug Des Devel Ther，2020，14:4149-4167.
［13］LICHTENBERGER LM,VIJAYAN KV.Are platelets the primary target of aspirin's remarkable anticancer activity［J］.Cancer Res,2019,79(15):3820-3823.
［14］XU XF，FAN JW，XIN JQ，et al.Aspirin ameliorates pancreatic inflammation and fibrosis by inhibiting COX-2 expression in experimental chronic pancreatitis［J］.J Inflamm Res，2022，15:4737-4749.
［15］KOH YC,LIU SY,WU JC，et al.A new metabolite:The effects of aminated tetrahydrocurcumin on inducible nitric oxide synthase and cyclooxygenase-2［J］.J Cancer Res Pract,2021，8(2):41.
［16］AHMED M，HUSSAIN AR，SIRAJ AK.Co-targeting of cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells［J］.Mol Cancer，2015，14(1):131.
［17］JIANG J,LIU JF,GAO P,et al.Effect of taking aspirin before diagnosis on the prognosis of esophageal squamous cell carcinoma and analysis of prognostic factors［J］.J Int Med Res，2022，50(4):3000605221089799.
［18］YAGHJYAN L,ELIASSEN AH,COLDITZ G，et al.Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression［J］.Breast Cancer Res,2022，24(1):89.
［19］BARDIA A，KEENAN TE，EBBERT JO，et al.Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women［J］.Mayo Clin Proc，2016，91(1):71-80.
［20］MCCARTHY AM,KUMAR NP,HE W,et al.Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer［J］.BMC Cancer，2020，20(1):347.
［21］ALAYEV A，HOLZ MK.mTOR signaling for biological control and cancer［J］.J Cell Physiol，2013，228(8):1658-1664.
［22］HYDBRING P，LARSSON LG.CDK2:A key regulator of the senescence control function of Myc［J］.Aging(Albany NY)，2010，2(4):244-250.
［23］ZHAO QQ，WANG ZP，WANG ZX，et al.Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models［J］.Oncol Lett，2016，12(4):2804-2810.
［24］ABDELMONSIF DA，SULTAN AS，EL-HADIDY WF，et al.Targeting AMPK,mTOR and β-catenin by combined metformin and aspirin therapy in HCC:An appraisal in Egyptian HCC patients［J］.Mol Diagn Ther,2018，22(1):115-127.
［25］MANN KM，YING H，JUAN J，et al.KRAS-related proteins in pancreatic cancer［J］.Pharmacol Ther，2016，168:29-42.
［26］SONG M，BODE AM，DONG Z，et al.AKT as a therapeutic target for cancer［J］.Cancer Res，2019，79(6):1019-1031.
［27］FENG MY，XIONG GB，CAO Z，et al.LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer［J］.J Exp Clin Cancer Res，2018，37(1):274.
［28］ZHOU HY，YUN X，SHU YQ，et al.Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial-mesenchymal transition［J］.Oncol Lett,2023，25(3):101.
［29］FRANCIPANE MG，LAGASSE E.mTOR pathway in colorectal cancer:An update［J］.Oncotarget，2014，5(1):49-66.
［30］HALL DCN，BENNDORF RA.Aspirin sensitivity of PIK3CA-mutated colorectal cancer:Potential mechanisms revisited［J］.Cell Mol Life Sci，2022，79(7):393.
［31］TURTURRO SB，NAJOR MS，RUBY CE，et al.Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin［J］.Breast Cancer Res Treat，2016，156(1):33-43.
［32］BOKU S，WATANABE M，SUKENO M，et al.Deactivation of glutaminolysis sensitizes PIK3CA-mutated colorectal cancer cells to aspirin-induced growth inhibition［J］.Cancers(Basel)，2020，12(5):1097.
［33］HEDBERG ML，PEYSER ND，BAUMAN JE，et al.Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer［J］.J Exp Med，2019，216(2):419-427.
［34］LIAO X，LOCHHEAD P，NISHIHARA R，et al.Aspirin use，tumor PIK3CA mutation，and colorectal-cancer survival［J］.N Engl J Med，2012，367(17):1596-1606.
［35］GEBAUER L，NIST A，MERNBERGER M，et al.Superior overall survival in patients with colorectal cancer，regular aspirin use，and combined wild-type PIK3CA and KRAS-mutated tumors［J］.Cancers(Basel)，2021，13(19):4959.
［36］CHEN ZH,WANG C,DONG H，et al.Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K Akt raptor pathway［J］.Mol Med，2020，26(1):14.
［37］GU MC，NISHIHARA R，CHEN Y，et al.Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells［J］.Oncotarget，2017，8(50):87379-87389.
［38］DOMINGO E，CHURCH DN，SIEBER O，et al.Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer［J］.J Clin Oncol，2013，31(34):4297-4305.
［39］WANG MM，YU HJ，LI ZJ，et al.Benefits and risks associated with low-dose aspirin use for the primary prevention of cardiovascular disease:A systematic review and Meta-analysis of randomized control trials and trial sequential analysis［J］.Am J Cardiovasc Drugs，2022，22(6):657-675.
［40］HOLMBERG D，GOTTLIEB-VEDI E，HEDBERG J，et al.Aspirin or statin use in relation to survival after surgery for esophageal cancer:A population-based cohort study［J］.BMC Cancer，2023，23(1):375.
［41］SHAHRIVAR M，WEIBULL CE，EKSTRM SMEDBY K，et al.Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study［J］.Cancer Med，2023，12(1):315-324.
［42］LFLING LL，STER NC，ANDREASSEN BK，et al.Low-dose aspirin，statins，and metformin and survival in patients with breast cancers:A Norwegian population-based cohort study［J］.Breast Cancer Res，2023,25(1):101.
［43］SEO SI，PARK CH，KIM TJ，et al.Aspirin，metformin，and statin use on the risk of gastric cancer:A nationwide population-based cohort study in Korea with systematic review and Meta-analysis［J］.Cancer Med，2022，11(4):1217-1231.
［44］MDGE JC，STALLMACH A，KLEEBUSCH L，et al.Meta-analysis of aspirin-guided therapy of colorectal cancer［J］.J Cancer Res Clin Oncol，2022，148(6):1407-1417.
［45］JIANG Y，SU ZX，LI CC，et al.Association between the use of aspirin and risk of lung cancer:Results from pooled cohorts and Mendelian randomization analyses［J］.J Cancer Res Clin Oncol，2021，147(1):139-151.
［46］TAO DL,TASSI YUNGA S,WILLIAMS CD,et al.Aspirin and antiplatelet treatments in cancer［J］.Blood，2021，137(23)：3201-3211.
［47］THUN MJ，JACOBS EJ，PATRONO C.The role of aspirin in cancer prevention［J］.Nat Rev Clin Oncol，2012，9：259-267.
［48］MA J,FAN ZH,TANG QL,et al.Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer［J］.Cell Death Dis，2020，11(7):530.
［49］BHARDWAJ A,EMBURY MD,ROJO RD,et al.Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer［J］.Breast Cancer Res Treat,2021,187(2):363-374.
［50］LIAO YH，HSU RJ，WANG TH，et al.Aspirin and primary cancer risk reduction in ischemic cardiac or cerebrovascular disease survivors:A nationwide population-based propensity-matched cohort study［J］.Cancers，2022，15(1):97.
［51］MILLER IS，KHAN S，SHIELS LP，et al.Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects［J］.Cancer Med，2022，11(20):3820-3836.